Twitter Beğeni Hilesi

#Breaking: NEJM publishes Phase III data demonstrating our medicine significantly reduced allergic reactions across multiple foods in people with #FoodAllergies. Learn more: gene.com/media/press-re…

#Breaking: Today we announced our CD20xCD3 bispecific antibody in combination with chemotherapy met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell #lymphoma, or #DLBCL. Learn more: gene.com/media/press-re…

#Breaking: We’re presenting new data from our Phase III study at #AANAM demonstrating sustained benefits for people living with relapsing and primary progressive multiple sclerosis. Learn more: gene.com/media/press-re…

#Breaking: The U.S. FDA approved our #targetedtherapy as the first adjuvant treatment for certain people with ALK+ early-stage #NSCLC. Learn more: gene.com/media/press-re…

ICYMI: The U.S. FDA approval of our #targetedtherapy for certain people with ALK+ early-stage #NSCLC is the first adjuvant treatment for this patient population. Learn more: bit.ly/3JqNUvU

#Breaking: Today we announced positive Phase Ib results for our dual GLP-1/GIP receptor agonist CT-388 in people with #obesity. Learn more: gene.com/media/press-re…

#Breaking: The U.S. FDA granted #BreakthroughTherapyDesignation to our investigational treatment regimen for people with PIK3CA-mutated HR+/HER2- locally advanced or metastatic #breastcancer. Learn more: gene.com/media/press-re…

#Breaking: Our investigational treatment regimen for people with PIK3CA-mutated HR+/HER2- locally advanced or metastatic #breastcancer was granted Priority Review by the U.S. FDA. Learn more: gene.com/media/press-re…

ICYMI: The U.S. FDA granted Priority Review to our investigational treatment regimen for people with PIK3CA-mutated HR+/HER2- locally advanced or metastatic #breastcancer, based on positive Phase III results with additional analyses presented at #ASCO24: gene.com/media/press-re…

#Breaking: During the Cure SMA Research & Clinical Care Meeting, we presented five-year data evaluating our medicine for spinal muscular atrophy (#SMA) in children with Type 1 SMA. Learn more: gene.com/media/press-re…

#ICYMI: During the Cure SMA Research & Clinical Care Meeting, we presented five-year data evaluating our medicine for spinal muscular atrophy (#SMA) in children with Type 1 SMA. Learn more: gene.com/media/press-re…

#Breaking: Today at #EHA2024, we’re presenting Phase III results of our CD20xCD3 bispecific antibody in combination with chemotherapy for people living with relapsed or refractory diffuse large B-cell #lymphoma, or #DLBCL. Learn more: gene.com/media/press-re…

#Breaking: Today, we provided an update on the Phase II/III trial evaluating our investigational anti-#TIGIT cancer immunotherapy in advanced non-squamous NSCLC. Learn more: gene.com/media/press-re…

#Breaking: The U.S. FDA approved the prefilled syringe version of our bispecific eye medicine, designed to simplify the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. Learn more: gene.com/media/press-re…

ICYMI: U.S. FDA approved the prefilled syringe version of our bispecific treatment for three retinal conditions that cause blindness. Read more: spr.ly/60199pa7B

#Breaking: Today, we reintroduced a first-of-its-kind treatment for wet age-related macular degeneration, giving patients a way to preserve their vision using an alternative to regular eye injections. Read more: gene.com/media/press-re…

ICYMI: We updated our first-of-its-kind eye treatment that gives people with wet age-related macular degeneration a way to preserve their vision using an alternative to regular eye injections. Learn more here: spr.ly/60179YYbS

#Breaking: Today we announced positive topline Phase I results for our investigational, once-daily, oral small molecule GLP-1 receptor agonist, CT-996, being developed for the treatment of both type 2 diabetes and obesity. Learn more: gene.com/media/press-re…

#Breaking: We shared new four-year data on the efficacy, safety and durability of our bispecific antibody for diabetic macular edema (DME) today as a late-breaker ASRS meeting at #ASRS2024. Read more: gene.com/media/press-re…

#Breaking: We shared new two-year Phase III results about a potentially new therapeutic approach for diabetic macular edema (DME) and diabetic retinopathy (DR) at #ASRS2024. Learn more about the data results here: gene.com/media/press-re…